Committed to significantly enhancing immunotherapy response
Combination therapies are being actively pursued as the next generation of immunotherapies. Sonnet’s versatile platform has been demonstrated to improve delivery of immunotherapy to the tumor and also overcomes past challenges with interleukins, which are viewed as a powerful tool in improving immunotherapy response rates.
Checkpoint inhibitors are the cornerstone of current cancer immunotherapy. These monoclonal antibodies can be very effective when the patient’s immune response to a tumor has been activated. However, adequate activation does not occur in the majority of patients. To reach their potential, checkpoint inhibitors will need other agents to help activate the immune response. Interleukins are a proven method for activating this response. By addressing past challenges with interleukins, Sonnet promises to unleash the true potential of checkpoint inhibition treatments.